GLP-1 for Teens: Is Wegovy Safe at 12?
STEP TEENS Trial Data, Growth Considerations & Parent Guide (2026)
Wegovy (semaglutide) became the first GLP-1 medication FDA-approved for adolescents aged 12 and up after the STEP TEENS trial. This guide covers the clinical evidence, BMI eligibility thresholds, potential impact on growth, and the key questions parents should ask their pediatrician.
Wegovy Ages 12+, STEP TEENS Trial & Adolescent Obesity Guidance (2026)
Semaglutide (Wegovy 2.4 mg) received FDA approval in December 2022 for chronic weight management in adolescents aged 12 and older with obesity (BMI ≥95th percentile) or overweight with weight-related complications. The STEP TEENS trial demonstrated 16.1% mean BMI reduction with semaglutide vs 0.6% with placebo over 68 weeks — a historic result for pediatric obesity treatment. GLP-1 therapy in adolescents raises important considerations including growth and development monitoring, bone density, nutrition during active growth, and the psychological dimensions of obesity treatment in young patients.
Why Track This Protocol with Shotlee
Clinical Evidence
Protocol Tracking
Outcome Monitoring
Side Effect Log
Progress Trends
Data-Driven Dosing
Guide FAQs
GLP-1 medications for teenagers — Wegovy (semaglutide) FDA-approved ages 12+. STEP TEENS trial data, BMI thresholds, growth considerations.
Yes. Shotlee supports tracking GLP-1 For Teens doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Glp1 For Teens research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Glp1 For Teens, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Glp1 For Teens protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Glp1 For Teens data in Shotlee to identify which combinations drive your best results.
References
- [1]Clinical TrialWeghuber D et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). N Engl J Med. 2022;387(24):2245-2257.
- [2]Clinical TrialWilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- [3]FDANovo Nordisk. Ozempic (semaglutide) Prescribing Information. U.S. Food and Drug Administration.
Track Your GLP-1 For Teens Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free